|Bid||375.00 x 1500|
|Ask||382.56 x 100|
|Day's Range||373.27 - 383.95|
|52 Week Range||340.09 - 543.55|
|PE Ratio (TTM)||34.61|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
CNBC's Meg Tirrell speaks with Leonard Schleifer, Regeneron CEO, about how the company will benefit from tax cuts, as well as pricing competition among drug companies.
Ministry of Health, Labor and Welfare (MHLW) in Japan has granted approval for the label expansion of Regeneron's (REGN) Dupixent.
Large cap biotech companies held a number of meetings with analysts and investors to discuss their plans for 2018, while both Celgene (CELG) and Regeneron (REGN) pre-announced 2017 results that were in-line to positive, compared to consensus estimates. Leerink's Geoffrey Porges and Bradley Canino take a look at the week in biotech, writing that Celgene and Regeneron were "predictably cautious" in their guidance, while the sector largely declined to estimate how tax changes will affect their profits just yet, although most companies have said that the tax bill is mostly positive. Porges and Canino write that big biotechs (save Regeneron) continue to suggest that acquisitions or licensing deals are on the table, as a means to juice pipelines, however no management teams "seemed convincing about having a firm idea of direction, size or type of transaction," leading them to believe that there won't be a big wave of M&A as a result of the tax bill: While a lack of capital may have stymied deals before, now management teams' lack of conviction, higher prices for takeout targets, and uncertainty about the future are the main obstacles.
Jim Cramer zoomed through his take on callers' favorite stocks, including a pharmaceutical name spooking investors.
The biotech sector performed impressively in 2017 and the momentum is expected to continue in 2018 driven by new drug approvals. Acquisitions will also remain in focus.
Focus this week was on preliminary results and 2018 outlooks provided by several companies including Celgene (CELG) at a healthcare conference.
One drug industry innovation that investors will surely appreciate: new ways of presenting tedious disclaimers before a company's presentation.
Regeneron (REGN) and partner Sanofi announced that they will expand their investment for the development cemiplimab in oncology, and label expansion of dupilumab in Type II allergic diseases.
Some of the world’s largest pharmaceutical companies are pooling resources to fund an ambitious genetic and medical database aimed at bolstering the search for new drugs.
Regeneron Pharmaceuticals Inc on Monday announced a collaboration with rival drugmakers that will speed its effort to collect genetic information on 500,000 people in the UK Biobank database, a project it believes could help accelerate new drug discovery and improve approval success rates. The data will be made available to health researchers anywhere in the world following a six-to-12-month period of exclusive access by consortium members, Regeneron said. "This is the first case where there will be large-scale human sequencing linked to large-scale human medical records that will also be publicly available," Regeneron President and Chief Scientific Officer George Yancopoulos said in a telephone interview.
France's Sanofi (SASY.PA) and U.S Regeneron (REGN.O) said on Monday they would inject an additional $1 billion in the development of cemiplimab, an antibody that could, if successful, be used to treat a wide range of cancers. In a statement, the two companies said they would also accelerate the co-development of dupilumab, a "multi-targeting" drug approved in the United States and Europe to treat eczema and undergoing tests to help treat asthma, nasal polyps, eosinophilic esophagitis and food allergies. "The investment in cemiplimab will be increased to $1.64 billion, an increase of approximately $1 billion over the initial 2015 agreement and Sanofi and Regeneron will continue to equally fund cemiplimab development," the two groups said.
In September 2017, Regeneron Pharmaceuticals Inc (NASDAQ:REGN) announced its latest earnings update, which signalled that the company benefited from a strong tailwind, eventuating to a double-digit earnings growth of 40.79%.Read More...
Momenta (MNTA), in collaboration with Mylan (MYL), plans to initiate a trial of M710, a proposed biosimilar of leading ophthalmology drug Eylea, in the first half of 2018.
Momenta Pharmaceuticals Inc and Mylan NV plan to begin a pivotal clinical trial of a biosimilar to Regeneron Pharmaceuticals Inc's blockbuster eye drug Eylea in the first half of this year, the two companies said on Wednesday. If successful, it would likely mark the first competition from a cheaper biosimilar of Eylea, although Regeneron says it has U.S. patent protection on the treatment until 2023. Germany's Formycon AG is far along in testing a biosimilar to Eylea rival Lucentis from Roche.
Regeneron is on deck to launch several drugs with blockbuster potential over the next few years, including a skin cancer treatment in 2018.